Date:3/11/2011

ted as of May 14, 2002 and previously amended on June 19, 2003, between the Company and OTC Corporate Transfer Service Company, as rights agent. The amendment increases the ownership threshold for determining "Acquiring Person" status under the Rights Agreement from 15%-18% and extends the "Final Expiration Date" for an additional two years, from May 31, 2012 to May 31, 2014.

In January 2011, the Company announced promising results from its study Chien-802, showing dramatic reductions in canine lipoma following injections with purified injectable collagenase. These results build upon an earlier dose escalation study from which the Company selected the dose for Chien-802.

In January 2011, the Company also announced the initiation of a larger clinical trial, Chien-803, for the same indication. On February 15, 2011, Auxilium filed a complaint against us in the Court of Common Pleas in Chester County, Pennsylvania.  We have voluntarily agreed to suspend this trial and will not be initiating any new trials using injectable collagenase in animals or humans pending a resolution of our dispute with Auxilium concerning our right to conduct clinical trials without the prior approval of the companies' Joint Development Committee.

In January 2011, Auxilium stated that it expects 2011 XIAFLEX U.S. net sales to be in the range of $50 million to $60 million.

In January 2011, Auxilium reported that, effective January 1, 2011, J0775 will be the code used to identify XIAFLEX when billed to Medicare, Medicaid and commercial health plans for reimbursement. The XIAFLEX specific CPT code is expected to be effective in January 2012.

In December 2010, the Company announced that The Journal of Hand Surgery published pivotal CORD II Phase III clinical trial of XIAFLEX.

In November 2010, the Company announced that it received a total of $426,000 in grant funding under the Qualifying Therapeutic Disco
'/>"/>

SOURCE BioSpecifics Technologies Corp. Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7
Related biology technology :

1. BioSpecifics Technologies Corp. Reports Second Quarter 2008 Financial Results
2. BioSpecifics Technologies Corp. Buys Down Royalties for Peyronies Disease
3. BioSpecifics Technologies Corp. Announces Appointment of Dr. Matthew Geller to Board of Directors
4. BioSpecifics Technologies Corp. to Present at Piper Jaffray 20th Annual Health Care Conference
5. BioSpecifics Technologies Corp. Announces Listing on NASDAQ Global Market
6. BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2008 Financial Results
7. BioSpecifics Technologies Corp. Announces FDA Acceptance of Biologics License Application With Priority Review for XIAFLEX(TM) for the Treatment of Dupuytrens Disease
8. BioSpecifics Technologies Corp. Reports First Quarter 2009 Financial Results
9. BioSpecifics Technologies Corp. Added to Russell 3000 and Russell 2000 Indexes
10. BioSpecifics Technologies Corp. to Present at CapStone Investments Third Annual Small-Cap Investor Conference
11. BioSpecifics Technologies Corp. to Host Conference Call to Report Second Quarter 2009 Financial Results on August 12, 2009